Paff Michelle, Alexandru-Abrams Daniela, Hsu Frank P K, Bota Daniela A
a Department of Neurological Surgery ; University of California, Irvine ; Orange , CA USA.
Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002.
Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.
多形性胶质母细胞瘤（GBM）是最常见的脑肿瘤类型，且无一例外都是致命的。这种疾病的社区治疗标准是对肿瘤进行大体或次全切除，随后进行放疗和替莫唑胺治疗。复发时可加用贝伐单抗以延长无进展生存期。在试图研发治疗GBM的新药时会遇到许多挑战，比如存在血脑屏障，大多数药物都无法透过。因此在过去几年里，人们将注意力转向了用免疫手段治疗这种毁灭性疾病。事实证明，靶向表皮生长因子受体III型变异体（EGFRvIII）是利用免疫系统攻击胶质母细胞瘤细胞的一种好方法。尽管仍在研发中，但这种方法有望成为朝着免疫定制药物治疗脑癌迈出的重要第一步。
